Ifp Advisors, Inc Cytom X Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$1.53 - $2.89 $339 - $641	222 New	222 $6,000
Q2 2022 Aug 12, 2022	SELL	$1.53 - $2.89 $339 - $641	-222 Closed	0 $0
Q3 2021 Oct 06, 2021	BUY	$4.32 - $6.43 $959 - $1,427	222 New	222 $1,000
Q2 2021 Jul 13, 2021	BUY	$6.33 - $9.91 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$6.6 - $9.0 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	SELL	$6.47 - $7.9 $504 - $616	-78 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$6.55 - $8.83 $510 - $688	78 New	78 $0
Q2 2020 Aug 05, 2020	BUY	$7.4 - $14.64 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$3.61 - $8.6 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	BUY	$5.17 - $8.91 $0 - $0	0 New	0 $0
Q3 2019 Nov 07, 2019	BUY	$7.38 - $12.25 $0 - $0	0 New	0 $0
Q3 2018 Oct 25, 2018	SELL	$18.04 - $26.41 $793 - $1,162	-44 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$21.38 - $29.68 $940 - $1,305	44 New	44 $0

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.